Equities

Torii Pharmaceutical Co Ltd

Torii Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,780.00
  • Today's Change30.00 / 0.80%
  • Shares traded16.50k
  • 1 Year change-2.07%
  • Beta0.5331
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast

The 2 analysts offering 12 month price targets for Torii Pharmaceutical Co Ltd have a median target of 4,035.00, with a high estimate of 4,270.00 and a low estimate of 3,800.00. The median estimate represents a 6.75% increase from the last price of 3,780.00.
High13.0%4,270.00
Med6.7%4,035.00
Low0.5%3,800.00

Dividends in JPY

In 2023, Torii Pharmaceutical Co Ltd reported a dividend of 120.00 JPY, which represents a 20.00% increase over last year. The 2 analysts covering the company expect dividends of 120.00 JPY for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)20.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.